Ningxia Zhongke Biotechnology Co (SHSE:600165) Beginning Cash Position: ¥272.4 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600165 Ningxia Zhongke Biotechnology Co Ltd SHSE:600165
52 GF Score
Price ¥3.14
GF Value ¥2.35
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ningxia Zhongke Biotechnology Co Beginning Cash Position?

Ningxia Zhongke Biotechnology Co SHSE:600165 -1.26% 52 Beginning Cash Position is ¥272.4 Mil as of Jun. 2026. GuruFocus rates SHSE:600165 with a GF Score™ of 52/100 and a GF Value™ of ¥2.35 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Ningxia Zhongke Biotechnology Co's Beginning Cash Position for the quarter that ended in Jun. 2026 was ¥272.4 Mil.

Ningxia Zhongke Biotechnology Co's quarterly Beginning Cash Position increased from Dec. 2025 (¥8.1 Mil) to Mar. 2026 (¥459.2 Mil) but then declined from Mar. 2026 (¥459.2 Mil) to Jun. 2026 (¥272.4 Mil).

Ningxia Zhongke Biotechnology Co's annual Beginning Cash Position declined from Dec. 2023 (¥42.1 Mil) to Dec. 2024 (¥21.8 Mil) and declined from Dec. 2024 (¥21.8 Mil) to Dec. 2025 (¥8.2 Mil).

Ningxia Zhongke Biotechnology Co Beginning Cash Position Related Terms

Ningxia Zhongke Biotechnology Co Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Ningxia Zhongke Biotechnology Co's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ningxia Zhongke Biotechnology Co Beginning Cash Position Chart

Ningxia Zhongke Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 182.23 86.25 42.12 21.84 8.19

Ningxia Zhongke Biotechnology Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.92 76.83 8.06 459.15 272.44
SHSE:600165
52GF Score
Ningxia Zhongke Biotechnology Co Ltd SHSE:600165
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ningxia Zhongke Biotechnology Co Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of ¥272.4 Mil mean?
Ningxia Zhongke Biotechnology Co (SHSE:600165) has a Beginning Cash Position of ¥272.4 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Ningxia Zhongke Biotechnology Co and its competitors.
Is Ningxia Zhongke Biotechnology Co's Beginning Cash Position too high?
Ningxia Zhongke Biotechnology Co's current Beginning Cash Position is ¥272.4 Mil. Overall, Ningxia Zhongke Biotechnology Co has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ningxia Zhongke Biotechnology Co's Beginning Cash Position compare to LIN and SHW?
Ningxia Zhongke Biotechnology Co's Beginning Cash Position of ¥272.4 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Chemicals company?
A good Beginning Cash Position depends on the Chemicals industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Ningxia Zhongke Biotechnology Co and its competitors. Ningxia Zhongke Biotechnology Co's current Beginning Cash Position is ¥272.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ningxia Zhongke Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Ningxia Zhongke Biotechnology Co (SHSE:600165) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥2.35, compared to a current price of ¥3.14 — trading 33.6% above its estimated fair value. The current Beginning Cash Position is ¥272.4 Mil. Ningxia Zhongke Biotechnology Co's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Ningxia Zhongke Biotechnology Co (SHSE:600165), the current Beginning Cash Position is ¥272.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ningxia Zhongke Biotechnology Co (SHSE:600165) Overvalued in 2026?

Based on GuruFocus' analysis, Ningxia Zhongke Biotechnology Co stock appears to be overvalued. The current stock price of ¥3.14 is trading 33.6% above its estimated GF Value™ of ¥2.35. GuruFocus considers Ningxia Zhongke Biotechnology Co to be Significantly Overvalued.

Key valuation signals for SHSE:600165:

  • Beginning Cash Position: ¥272.4 Mil
  • GF Value™: ¥2.35 vs. price of ¥3.14 (33.6% above fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the SHSE:600165 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ningxia Zhongke Biotechnology Co Business Description

Address Hebin Street, Ningxia Hui Autonomous Region, Huinong District, Shizuishan, CHN, 750002
Ningxia Zhongke Biotechnology Co Ltd is engaged in the production and sales of activated carbon products, preparation and storage of stem cells, trade and other businesses, as well as lauric acid.
52GF Score

Get the complete analysis for SHSE:600165

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥3.14
Price
¥2.35
GF Value